Boston Scientific (BSX) EVP Discloses Shares, RSUs and Option Grants
Rhea-AI Filing Summary
Boston Scientific executive Susan O'Connor, EVP, Global Operations, reported her equity holdings in the company. She directly owns 3,885 shares of Boston Scientific common stock. In addition, she holds multiple grants of restricted stock units (RSUs) that each convert into one share of common stock as they vest over time, with various awards continuing to vest annually on the anniversaries of their original grant dates through periods ending between 2026 and 2029.
O'Connor also holds several stock options giving her the right to buy additional Boston Scientific shares at fixed exercise prices ranging from $37.50 to $106.14 per share, with expiration dates from February 2031 through February 2035. These options generally vest in four equal annual installments starting one year after the respective grant dates. The filing reflects her current beneficial ownership and outstanding equity-based compensation.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. This amount represents the unvested portion of RSUs awarded on February 12, 2024, which will continue to vest in three remaining installments on the anniversary of the date of grant. Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. This amount represents the unvested portion of RSUs awarded on February 14, 2023, which will continue to vest in two remaining installments on the anniversary of the date of grant. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. This amount represents the unvested portion of RSUs awarded on February 16, 2022, which will continue to vest in one remaining installment on the anniversary of the date of grant. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant. This amount represents the unvested portion of RSUs awarded on May 2, 2022, which will continue to vest in one remaining installment on the anniversary of the date of grant. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on September 2, 2026, the first anniversary of the date of grant. Grant to the reporting person of an option to purchase 13,822 shares of common stock vesting in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Grant to the reporting person of an option to purchase 12,050 shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Grant to the reporting person of an option to purchase 14,290 shares of common stock vesting in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Grant to the reporting person of an option to purchase 12,998 shares of common stock vesting in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Grant to the reporting person of an option to purchase 5,151 shares of common stock vesting in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.
FAQ
What restricted stock units (RSUs) are reported in this Boston Scientific (BSX) filing?
The filing lists multiple restricted stock unit awards, each representing a commitment to deliver one share of Boston Scientific common stock. These RSUs vest in four equal annual installments, with grants having vesting schedules beginning on anniversaries of grant dates in February and May 2023, 2024, 2025, 2026, and September 2026.
What stock options does the Boston Scientific (BSX) executive hold and at what exercise prices?
The executive holds several stock options (rights to buy) Boston Scientific common stock: 13,822 shares at $37.5, 12,050 shares at $44.19, 14,290 shares at $47.28, 12,998 shares at $64.99, and 5,151 shares at $106.14.
When do the Boston Scientific (BSX) stock options reported here expire?
The stock options held by the executive expire on 02/17/2031, 02/16/2032, 02/14/2033, 02/12/2034, and 02/13/2035, depending on the specific grant.
How do the RSU vesting schedules work for the Boston Scientific (BSX) executive?
For each RSU grant, shares of common stock are issued in four equal annual installments, typically beginning on the first anniversary of the grant date. Remaining unvested portions continue to vest annually on those anniversaries until fully vested.
What is the executive’s role and relationship to Boston Scientific (BSX)?
The reporting person is an officer of Boston Scientific, serving as EVP, Global Operations. The filing reports her beneficial ownership of company equity as required for insiders.
